Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1801. Type 1 diabetes. (Abstract)

Type 1 diabetes. Type 1 diabetes accounts for only about 5-10% of all cases of diabetes; however, its incidence continues to increase worldwide and it has serious short-term and long-term implications. The disorder has a strong genetic component, inherited mainly through the HLA complex, but the factors that trigger onset of clinical disease remain largely unknown. Management of type 1 diabetes is best undertaken in the context of a multidisciplinary health team and requires continuing (...) attention to many aspects, including insulin administration, blood glucose monitoring, meal planning, and screening for comorbid conditions and diabetes-related complications. These complications consist of microvascular and macrovascular disease, which account for the major morbidity and mortality associated with type 1 diabetes. Newer treatment approaches have facilitated improved outcomes in terms of both glycaemic control and reduced risks for development of complications. Nonetheless, major

2006 Lancet

1802. Narrative review: ketosis-prone type 2 diabetes mellitus. (Abstract)

Narrative review: ketosis-prone type 2 diabetes mellitus. Several investigators have reported that more than half of African-American persons with new diagnoses of diabetic ketoacidosis have clinical, metabolic, and immunologic features of type 2 diabetes during follow-up. These patients are usually obese, have a strong family history of diabetes, have a low prevalence of autoimmune markers, and lack a genetic association with HLA. Their initial presentation is acute, with a few days to weeks (...) to several years. The absence of autoimmune markers and the presence of measurable insulin secretion have proven useful in predicting near-normoglycemic remission and long-term insulin dependence in adult patients with a history of diabetic ketoacidosis. This clinical presentation is commonly reported in African and African-American persons but is also observed in Hispanic persons and those from other minority ethnic groups. The underlying mechanisms for beta-cell dysfunction in ketosis-prone type 2

2006 Annals of Internal Medicine

1803. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Full Text available with Trip Pro

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher

2006 Evidence-Based Medicine

1804. The clarity, timing, and authority of the delivery of a diagnosis of type 2 diabetes had important meaning for patients Full Text available with Trip Pro

The clarity, timing, and authority of the delivery of a diagnosis of type 2 diabetes had important meaning for patients The clarity, timing, and authority of the delivery of a diagnosis of type 2 diabetes had important meaning for patients | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The clarity, timing, and authority of the delivery of a diagnosis of type 2 diabetes had important meaning for patients Article Text Qualitative

2006 Evidence-Based Mental Health

1805. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113) Inhaled insulin for the treatment of type 1 and type 2 diabetes | Guidance | NICE Inhaled insulin for the treatment of type 1 and type 2 diabetes Technology appraisal guidance [TA113] Published date: 13 December 2006 Guidance In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer

2006 National Institute for Health and Clinical Excellence - Technology Appraisals

1806. Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2

Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2 Executive Summary IQWiG Reports - Commission No. A05-04 Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2 1 1 Executive summary of the final report “Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2” (Version 1.0; Status: 15.12.2005). Please note: This document is provided as a service by IQWiG to English-language readers. However, solely the German original full report (...) is absolutely authoritative and legally binding. Executive summary of final report A05-04 Version 1.0 15.12.2005 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Benefit assessment of rapid-acting insulin analogues for the treatment of diabetes mellitus type 2 Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-04 Address of publisher: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105

2006 Institute for Quality and Efficiency in Healthcare (IQWiG)

1807. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. Full Text available with Trip Pro

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer (...) studies have been less clear.To evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM.Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multiracial/ethnic Chicago metropolitan area between October 2003 and May 2006. The treatment period was 72 weeks (1-week follow-up). CIMT images were captured by a single ultrasonographer at 1 center and read

2006 JAMA Controlled trial quality: predicted high

1808. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Full Text available with Trip Pro

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin (...) or sulphonylureas.1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a haemoglobin A1c (HbA1c) concentration of 6.5-10.0% (mean 7.3% [SD 0.9] at baseline) already on metformin or sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus

2006 Lancet Controlled trial quality: predicted high

1809. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. (Abstract)

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lifestyle interventions can prevent the deterioration of impaired glucose tolerance to manifest type 2 diabetes, at least as long as the intervention continues. In the extended follow-up of the Finnish Diabetes Prevention Study, we assessed the extent to which the originally-achieved lifestyle changes and risk reduction remain after discontinuation of active (...) , the incidence of type 2 diabetes was 4.3 and 7.4 per 100 person-years in the intervention and control group, respectively (log-rank test p=0.0001), indicating 43% reduction in relative risk. The risk reduction was related to the success in achieving the intervention goals of weight loss, reduced intake of total and saturated fat and increased intake of dietary fibre, and increased physical activity. Beneficial lifestyle changes achieved by participants in the intervention group were maintained after

2006 Lancet Controlled trial quality: uncertain

1810. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries

Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries Ackroyd R, Mouiel J, Chevallier J M, Daoud F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two bariatric operations, adjustable gastric banding (AGB) and gastric bypass (GBP), for the treatment of obesity in patients with Type 2 diabetes mellitus (T2DM). Obesity was defined as a body mass index (BMI) of at least 35 kg/m2. Type of intervention Treatment

2006 NHS Economic Evaluation Database.

1811. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials

Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

1812. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials

Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

1813. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK Beale S, Bagust A, Shearer A T, Martin A, Hulme L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two treatment options for patients with Type 2 diabetes. Each treatment option comprised six steps and differed in the fourth and fifth steps regarding medical treatment following the failure of metformin monotherapy. The first three steps comprised diet and exercise

2006 NHS Economic Evaluation Database.

1814. Evaluation of the benefits and harms of rapid-acting insulin analogues in patients with diabetes mellitus type 2

Evaluation of the benefits and harms of rapid-acting insulin analogues in patients with diabetes mellitus type 2 Evaluation of the benefits and harms of rapid-acting insulin analogues in patients with diabetes mellitus type 2 Evaluation of the benefits and harms of rapid-acting insulin analogues in patients with diabetes mellitus type 2 Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of rapid-acting insulin analogues in patients with diabetes mellitus type 2. Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aim of this evaluation was to compare the effects of long-term treatment

2006 Health Technology Assessment (HTA) Database.

1815. Inhaled insulin for the treatment of type 1 and type 2 diabetes

Inhaled insulin for the treatment of type 1 and type 2 diabetes Inhaled insulin for the treatment of type 1 and type 2 diabetes Inhaled insulin for the treatment of type 1 and type 2 diabetes National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Inhaled insulin (...) for the treatment of type 1 and type 2 diabetes. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 113. 2006 Authors' objectives The aim of this review is to provide guidance on the use of inhaled insulin for the treatmentof type 1 and type 2 diabetes. Authors' conclusions Inhaled insulin is not recommended as a routine treatment for people with type 1 or type 2 diabetes. Inhaled insulin should only be used as a possible treatment for people with type 1 or type

2006 Health Technology Assessment (HTA) Database.

1816. Inhaled insulin for type 2 diabetes

Inhaled insulin for type 2 diabetes Inhaled insulin for type 2 diabetes Inhaled insulin for type 2 diabetes Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Inhaled insulin for type 2 diabetes. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Patients with type 2 diabetes require exogenous insulin when diet and exercise or oral hypoglycemic (...) agents (OHAs) no longer provide adequate glycemic control. Inadequate glycemic control can lead to serious metabolic and long-term vascular complications. Conventional insulin therapy involves multiple, daily, subcutaneous injections. Recently, oral inhalation systems have been developed that deliver short-acting insulin, with the goal of providing a more tolerable delivery system and encouraging earlier acceptance of insulin therapy in patients with type 2 diabetes. Final publication URL The report

2006 Health Technology Assessment (HTA) Database.

1817. Inhaled insulin for type 1 diabetes

Inhaled insulin for type 1 diabetes Inhaled insulin for type 1 diabetes Inhaled insulin for type 1 diabetes Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Inhaled insulin for type 1 diabetes. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Patients with type 1 diabetes require exogenous insulin to control blood glucose levels and to help (...) assigned by CRD MeSH Administration, Inhalation; Diabetes Mellitus, Type 1 /drug therapy; Hypoglycemic Agents /therapeutic use; Insulin /therapeutic use Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32006001575 Date bibliographic record published 08

2006 Health Technology Assessment (HTA) Database.

1818. Chronic intermittent intravenous insulin therapy (CIIIT) for type 1 diabetes mellitus

Chronic intermittent intravenous insulin therapy (CIIIT) for type 1 diabetes mellitus Chronic intermittent intravenous insulin therapy (CIIIT) for type 1 diabetes mellitus Chronic intermittent intravenous insulin therapy (CIIIT) for type 1 diabetes mellitus Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chronic intermittent intravenous insulin therapy (CIIIT (...) ) for type 1 diabetes mellitus. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives The purpose of chronic intermittent intravenous insulin therapy (CIIIT) is to reduce symptoms, improve glycemic control, and prevent diabetic sequelae in patients with type 1 diabetes mellitus who do not respond adequately to conventional percutaneous intensive insulin therapy (IIT). CIIIT is not intended to replace IIT but rather to supplement it. Final publication URL The report may be purchased from

2006 Health Technology Assessment (HTA) Database.

1819. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons

Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

1820. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.